Healthequity (NASDAQ:HQY) had its price objective raised by investment analysts at Robert W. Baird from $48.00 to $49.00 in a research note issued to investors on Wednesday. The firm presently has a “neutral” rating on the stock. Robert W. Baird’s price objective points to a potential downside of 0.12% from the stock’s current price.

A number of other research firms also recently issued reports on HQY. BidaskClub downgraded Healthequity from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. JPMorgan Chase & Co. decreased their target price on Healthequity from $52.00 to $51.00 and set an “overweight” rating for the company in a research report on Wednesday, January 24th. Zacks Investment Research downgraded Healthequity from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. Chardan Capital raised their target price on Healthequity from $58.00 to $62.00 and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $56.00 target price on shares of Healthequity in a research report on Tuesday, December 5th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $57.17.

Shares of Healthequity (NASDAQ:HQY) traded down $2.39 on Wednesday, hitting $49.06. The company had a trading volume of 1,192,244 shares, compared to its average volume of 446,021. The stock has a market capitalization of $2,980.00, a P/E ratio of 66.30, a price-to-earnings-growth ratio of 1.95 and a beta of 1.70. Healthequity has a one year low of $37.62 and a one year high of $55.31.

Healthequity (NASDAQ:HQY) last issued its quarterly earnings results on Tuesday, December 5th. The company reported $0.17 EPS for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.04. Healthequity had a return on equity of 14.47% and a net margin of 21.08%. The company had revenue of $56.80 million during the quarter, compared to the consensus estimate of $55.27 million. During the same period last year, the business posted $0.10 earnings per share. Healthequity’s revenue was up 31.0% on a year-over-year basis. equities analysts forecast that Healthequity will post 0.73 EPS for the current fiscal year.

In other news, Director Frank Medici sold 49,900 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $52.01, for a total value of $2,595,299.00. Following the completion of the transaction, the director now directly owns 6,381 shares of the company’s stock, valued at $331,875.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Ashley Dreier sold 12,000 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $52.00, for a total value of $624,000.00. Following the completion of the transaction, the vice president now directly owns 17,652 shares of the company’s stock, valued at $917,904. The disclosure for this sale can be found here. Insiders sold 371,426 shares of company stock valued at $18,749,703 over the last ninety days. Corporate insiders own 19.00% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Healthequity by 3.0% during the second quarter. Vanguard Group Inc. now owns 4,237,298 shares of the company’s stock valued at $211,145,000 after buying an additional 122,061 shares during the period. Wasatch Advisors Inc. lifted its stake in Healthequity by 2.2% during the second quarter. Wasatch Advisors Inc. now owns 2,442,180 shares of the company’s stock worth $121,694,000 after purchasing an additional 52,885 shares during the last quarter. State Street Corp lifted its stake in Healthequity by 10.8% during the second quarter. State Street Corp now owns 1,172,117 shares of the company’s stock worth $58,411,000 after purchasing an additional 114,294 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Healthequity by 49.5% during the third quarter. Wells Fargo & Company MN now owns 1,108,410 shares of the company’s stock worth $56,063,000 after purchasing an additional 366,925 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Healthequity by 116.4% during the fourth quarter. Victory Capital Management Inc. now owns 1,031,711 shares of the company’s stock worth $48,139,000 after purchasing an additional 555,027 shares during the last quarter. 98.20% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Robert W. Baird Boosts Healthequity (HQY) Price Target to $49.00” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2018/02/07/robert-w-baird-boosts-healthequity-hqy-price-target-to-49-00.html.

Healthequity Company Profile

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.